Aleixandre M A, Puerro M, Pintado A
Department of Pharmacology, School of Medicine, Complutense University, Madrid, Spain.
Naunyn Schmiedebergs Arch Pharmacol. 1995 May;351(5):500-6. doi: 10.1007/BF00171041.
TMB-8 has been characterized as an inhibitor of the release of Ca2+ from intracellular pools. We have studied the modification of the pressor responses to selective alpha 1-adrenoceptor agonists (methoxamine and phenylephrine), and to selective alpha 2-adrenoceptor agonists (B-HT 920 and B-HT 933) in pithed rats, produced by TMB-8. We have compared this modification with that produced by the calcium antagonist nifedipine. Nifedipine (100 micrograms/kg, 300 micrograms/kg, and 1000 micrograms/kg) inhibited in a dose-dependent manner the pressor responses to the alpha 1- and alpha 2-adrenoceptor agonists, the dose-response curves to the alpha 2-adrenoceptor agonists being shifted further to the right. TMB-8 at a dose of 3000 micrograms/kg did not modify the pressor effects of the alpha 1-adrenoceptor agonists, and neither did it reinforce the inhibition of such responses produced by nifedipine. By contrast, TMB-8 pretreatment (0.03 micrograms/kg, 0.3 micrograms/kg, 3 micrograms/kg, 30 micrograms/kg, 300 micrograms/kg and 3000 micrograms/kg) inhibited the responses to both alpha 2-adrenoceptor agonists, the inhibition being more pronounced with B-HT 920. A similar effect was obtained with 0.03 micrograms/kg TMB-8 and 0.3 microgram/kg TMB-8, particularly in the case of B-HT 920. It was stronger with higher doses, but similar for all doses over 3 micrograms/kg. The inhibition of the pressor responses mediated by the stimulation of alpha 2-adrenoceptors by TMB-8 was less in rats treated with the Ca2+ entry promoter BAY K 8644 (300 micrograms/kg), and could also be reduced by the continuous infusion of CaCl2 (0.25 microgram/min).(ABSTRACT TRUNCATED AT 250 WORDS)
TMB - 8已被确定为细胞内钙库中钙离子释放的抑制剂。我们研究了TMB - 8对去脑大鼠对选择性α1肾上腺素能受体激动剂(甲氧明和去氧肾上腺素)以及选择性α2肾上腺素能受体激动剂(B - HT 920和B - HT 933)升压反应的影响。我们将这种影响与钙拮抗剂硝苯地平产生的影响进行了比较。硝苯地平(100微克/千克、300微克/千克和1000微克/千克)以剂量依赖性方式抑制对α1和α2肾上腺素能受体激动剂的升压反应,α2肾上腺素能受体激动剂的剂量 - 反应曲线进一步右移。3000微克/千克剂量的TMB - 8未改变α1肾上腺素能受体激动剂的升压作用,也未增强硝苯地平对这些反应的抑制作用。相比之下,TMB - 8预处理(0.03微克/千克、0.3微克/千克、3微克/千克、30微克/千克、300微克/千克和3000微克/千克)抑制了对两种α2肾上腺素能受体激动剂的反应,对B - HT 920的抑制作用更明显。0.03微克/千克和0.3微克/千克的TMB - 8产生了类似的效果,特别是对于B - HT 920。高剂量时作用更强,但3微克/千克以上的所有剂量作用相似。在用钙离子内流促进剂BAY K 8644(300微克/千克)处理的大鼠中,TMB - 8对由α2肾上腺素能受体刺激介导的升压反应的抑制作用较小,持续输注氯化钙(0.25微克/分钟)也可降低这种抑制作用。(摘要截取自250字)